BrightHeart

Lam-Rachlin et. al., “Use of Artificial Intelligence–Based Software to Aid in the Identification of Ultrasound Findings Associated With Fetal Congenital Heart Defects,” Obstetrics & Gynecology, 2025.
Rebarber et. al., “Optimizing screening for severe congenital heart defects on prenatal ultrasound using eight suspicious findings and artificial intelligence”, ISUOG abstract, 2025.
B-Right Views is a Class II FDA-cleared and a Class IIa CE marked (Notified Body: 3022) medical device, please refer to product regulatory information for more details.
B-Right Screen is a Class II FDA-cleared and a Class IIa CE marked (Notified Body: 3022) medical device, please refer to product regulatory information for more details.
https://childrensheartlink.org/congenital-heart-disease-facts/#:~:text=Every%205%20minutes%2C%2010%20children,1.3%20million%20children%20each%20year.
https://pmc.ncbi.nlm.nih.gov/articles/PMC7317409/
https://pubmed.ncbi.nlm.nih.gov/12084585/
https://pubmed.ncbi.nlm.nih.gov/18657826/
https://pubmed.ncbi.nlm.nih.gov/32795094/
Lam-Rachlin et. al., “Enhancing Ultrasound Standard View Completion in Fetal Heart Screening with an AI Software,” ISUOG abstract, 2025.
Zelop et al., “Artificial Intelligence Accurately Detects Fetal Ultrasound Findings Suspicious For Major Congenital Heart Defects,” Obstetrics & Gynecology, 2025. *Stats presented among conclusive cases.
Note: Images shown may represent the range of products and differ from versions, or be for illustration purposes only, and may not be an exact representation of the product.
For use only in countries with applicable health authority registrations: please contact us for more information.

Contact